The Saphnelo Pen approval enhances patient convenience and could drive increased market share and revenue in the SLE space. Traders should monitor uptake trends and future sales guidance, as improved accessibility may accelerate growth in this key immunology asset.
Price Chart
Executive Summary
AstraZeneca's Saphnelo (anifrolumab) has been approved by the FDA for self-administration via a once-weekly autoinjector (Saphnelo Pen) for adult patients with systemic lupus erythematosus (SLE), expanding access beyond the current IV infusion. The approval is based on Phase III TULIP-SC trial data showing statistically significant and clinically meaningful reduction in disease activity.
Key Facts
- FDA approved Saphnelo for subcutaneous self-administration using the Saphnelo Pen, a once-weekly autoinjector, for adult SLE patients on standard therapy.
- Approval based on Phase III TULIP-SC trial results demonstrating statistically significant and clinically meaningful reduction in disease activity versus placebo.
- Saphnelo Pen offers patients greater flexibility and convenience compared to the current IV infusion, potentially increasing adoption and market penetration.
- Saphnelo IV is already approved in over 70 countries; subcutaneous formulation previously approved in EU and Japan.
- Over 40,000 patients globally have been treated with Saphnelo to date.
Financial Impact
Mid-teens royalty payment to BMS on US sales; no specific revenue figures disclosed but expansion of administration route expected to increase uptake and revenue over time.
Risk Factors
- Competition from other lupus therapies may limit market penetration.
- Royalty payments to BMS on US sales reduce net profit margin.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003936 |
| Document: 0001654954-26-003936-index-headers.html | 0001654954-26-003936 |
| Document: 0001654954-26-003936-index.html | 0001654954-26-003936 |
| Document: 0001654954-26-003936.txt | 0001654954-26-003936 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $157.02 (−2.98%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $157.02 (+4.13%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $157.02 (−1.89%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $157.02 (+3.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access